Abstract
Summary
In contrast to tumor bearing hamsters, in which 95% (59 of 62) of the animals in this series developed complement fixing (C-F) antibodies against homologous adenovirus type 12 tumors, only 18% (7 of 40) of the C3Hf/Gs mice bearing adenovirus type 12 transplant tumors developed C-F antibodies against homologous mouse tumors. Only 7% (5 of 69) of the tumor bearing mice developed C-F antibody when tested against adenovirus type 12 hamster tumor antigen. Also, there was no significant correlation in the mouse between tumor size and antibody titer as there was in the hamster. The disparity between the development of antibodies in the mouse and the hamster is not accounted for by absence of antigen in the mouse tumors because most contained antigen as determined by reactivity with positive hamster sera.
Get full access to this article
View all access options for this article.